相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
Genomics and Immunomics in the Treatment of Urothelial Carcinoma
Veronica Mollica et al.
CURRENT ONCOLOGY (2022)
Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial
Thomas Powles et al.
NATURE MEDICINE (2021)
TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor
Ivan de Kouchkovsky et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
Matthew D. Galsky et al.
LANCET (2020)
Mesenchymal and MAPK Expression Signatures Associate with Telomerase Promoter Mutations in Multiple Cancers
Josh Lewis Stern et al.
MOLECULAR CANCER RESEARCH (2020)
Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis
Nazli Dizman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma
Veronica Mollica et al.
CANCERS (2020)
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Thomas Powles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti-CTLA4 treatment
Huahua Li et al.
CANCER MEDICINE (2020)
Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma
Sumit Isharwal et al.
EUROPEAN UROLOGY FOCUS (2019)
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Arjun V. Balar et al.
LANCET (2017)
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
Arjun V. Balar et al.
LANCET ONCOLOGY (2017)
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Padmanee Sharma et al.
LANCET ONCOLOGY (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma Updated Results From a Phase 1/2 Open-label Study
Thomas Powles et al.
JAMA ONCOLOGY (2017)
A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition
Milena P. Mak et al.
CLINICAL CANCER RESEARCH (2016)
Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications
Boaz Kurtis et al.
ANNALS OF DIAGNOSTIC PATHOLOGY (2016)
A Prospective Blinded Evaluation of Urine-DNA Testing for Detection of Urothelial Bladder Carcinoma in Patients with Gross Hematuria
Christina M. Dahmcke et al.
EUROPEAN UROLOGY (2016)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al.
LANCET (2016)
Understanding TERT Promoter Mutations: A Common Path to Immortality
Robert J. A. Bell et al.
MOLECULAR CANCER RESEARCH (2016)
Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications
Tiantian Liu et al.
GENES (2016)
Frequency of TERT Promoter Mutations in Prostate Cancer
Robert Stoehr et al.
PATHOBIOLOGY (2015)
TERT promoter mutations and telomerase reactivation in urothelial cancer
Sumit Borah et al.
SCIENCE (2015)
Cancer-associated TERT promoter mutations abrogate telomerase silencing
Kunitoshi Chiba et al.
ELIFE (2015)
Low frequency of TERT promoter mutations in gastrointestinal stromal tumors (GISTs)
Nathalia C. Campanella et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2015)
ALTernative Telomere Maintenance and Cancer
Robert L. Dilley et al.
TRENDS IN CANCER (2015)
TERT promoter mutations in cancer development
Barbara Heidenreich et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2014)
Telomerase Reverse Transcriptase Gene Promoter Mutations Help Discern the Origin of Urogenital Tumors: A Genomic and Molecular Study
Song Wu et al.
EUROPEAN UROLOGY (2014)
Telomerase Reverse Transcriptase Promoter Mutations in Bladder Cancer: High Frequency Across Stages, Detection in Urine, and Lack of Association with Outcome
Yves Allory et al.
EUROPEAN UROLOGY (2014)
Comprehensive Mutation Analysis of the TERT Promoter in Bladder Cancer and Detection of Mutations in Voided Urine
Carolyn D. Hurst et al.
EUROPEAN UROLOGY (2014)
Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy
Ren-Chin Wu et al.
JOURNAL OF PATHOLOGY (2014)
TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR
Kun Wang et al.
ONCOTARGET (2014)
Assessment of DNA Damage and Telomerase Activity in Exfoliated Urinary Cells as Sensitive and Noninvasive Biomarkers for Early Diagnosis of Bladder Cancer in Ex-Workers of a Rubber Tyres Industry
Delia Cavallo et al.
BIOMED RESEARCH INTERNATIONAL (2014)
The Role of Telomere Biology in Cancer
Lifeng Xu et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 8 (2013)
Finding the end: recruitment of telomerase to telomeres
Jayakrishnan Nandakumar et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2013)
TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism
P. Sivaramakrishna Rachakonda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
Patrick J. Killela et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
TERT Promoter Mutations in Familial and Sporadic Melanoma
Susanne Horn et al.
SCIENCE (2013)
Highly Recurrent TERT Promoter Mutations in Human Melanoma
Franklin W. Huang et al.
SCIENCE (2013)
Telomerase: central regulator of all of the hallmarks of cancer
Kee Chung Low et al.
TRENDS IN BIOCHEMICAL SCIENCES (2013)
Frequency of TERT promoter mutations in human cancers
Joao Vinagre et al.
NATURE COMMUNICATIONS (2013)
Follow-up procedures for non-muscle-invasive bladder cancer: an update
Anastasios Anastasiadis et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
It all comes together at the ends: Telomerase structure, function, and biogenesis
Joshua D. Podlevsky et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Bladder cancer: translating molecular genetic insights into clinical practice
Liang Cheng et al.
HUMAN PATHOLOGY (2011)
Telomerase: Structure, functions, and activity regulation
M. I. Zvereva et al.
BIOCHEMISTRY-MOSCOW (2010)
The end is nigh
Friedrich C. Luft
JOURNAL OF MOLECULAR MEDICINE-JMM (2010)
Alternative lengthening of telomeres: models, mechanisms and implications
Anthony J. Cesare et al.
NATURE REVIEWS GENETICS (2010)
Telomere biology in healthy aging and disease
Hisko Oeseburg et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2010)
How Telomeres Solve the End-Protection Problem
Titia de Lange
SCIENCE (2009)
Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers
Satoru Kyo et al.
CANCER SCIENCE (2008)
Telomeres and human disease: Ageing, cancer and beyond
MA Blasco
NATURE REVIEWS GENETICS (2005)
Urothelial tumorigenesis: A tale of divergent pathways
XR Wu
NATURE REVIEWS CANCER (2005)
Chromosomal imbalances in primary and metastatic melanomas: over-representation of essential telomerase genes
C Pirker et al.
MELANOMA RESEARCH (2003)
Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT)
JC Poole et al.
GENE (2001)
分享论文
